Literature DB >> 2835475

Plasma and tissue pharmacokinetics of human interferon-alpha in the rat after its intravenous administration.

N H Greig1, T T Soncrant, K M Wozniak, S I Rapoport.   

Abstract

The pharmacokinetic distribution of human lymphoblastoid interferon (IFN-alpha), (Wellferon, Burroughs Wellcome Company, Research Triangle Park, NC) in plasma and seven tissues was studied for up to 4 hr after intravascular administration as a bolus, 2 x 10(5) U/100 g, or as a 5-min infusion, 2 x 10(6) U/100 g, into anesthetized male Fischer 344 rats. IFN-alpha disappeared rapidly from plasma with elimination T 1/2 of 47 and 68 min, respectively, and was preferentially taken up by the kidney as compared with other organs. After i.v. injection, significant amounts of IFN-alpha, in order of descending concentration, were detected in kidney, lung, spleen, liver and lymph node, but not in brain or skeletal muscle. After a 5-min IFN-alpha infusion, significant amounts, in order of descending priority, were detected in kidney, lung, spleen, lymph node, liver, muscle and brain. The pharmacokinetic parameters of IFN-alpha are described for plasma and different tissues. After intravascular IFN-alpha administration, high blood levels are achieved immediately which encourages rapid distribution throughout body tissues, albeit at the cost of a high renal catabolic loss, in concentrations that can be predicted from our study.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2835475

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  14 in total

1.  Modification of the P-glycoprotein dependent pharmacokinetics of digoxin in rats by human recombinant interferon-alpha.

Authors:  Makrem Ben Reguiga; Laurence Bonhomme-Faivre; Simone Orbach-Arbouys; Robert Farinotti
Journal:  Pharm Res       Date:  2005-08-16       Impact factor: 4.200

2.  Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokine-induced depression.

Authors:  Jennifer C Felger; Oyetunde Alagbe; Fang Hu; Deborah Mook; Amanda A Freeman; Mar M Sanchez; Ned H Kalin; Emiliangelo Ratti; Charles B Nemeroff; Andrew H Miller
Journal:  Biol Psychiatry       Date:  2007-08-02       Impact factor: 13.382

3.  Transport of desglycinamide-arginine vasopressin across the blood-brain barrier in rats as evaluated by the unit impulse response methodology.

Authors:  J B van Bree; S Tio; A G de Boer; M Danhof; J C Verhoef; D D Breimer
Journal:  Pharm Res       Date:  1990-03       Impact factor: 4.200

Review 4.  Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications.

Authors:  J C Felger; F E Lotrich
Journal:  Neuroscience       Date:  2013-05-03       Impact factor: 3.590

5.  Involvement of central opioid systems in human interferon-alpha induced immobility in the mouse forced swimming test.

Authors:  M Makino; Y Kitano; C Komiyama; M Hirohashi; K Takasuna
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

6.  Effects of chronic administration of interferon alpha A/D on serotonergic receptors in rat brain.

Authors:  S Abe; T Hori; T Suzuki; A Baba; H Shiraishi; T Yamamoto
Journal:  Neurochem Res       Date:  1999-03       Impact factor: 3.996

7.  Pharmacokinetics of an extended-release human interferon alpha-2b formulation.

Authors:  A Bonetti; S Kim
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 8.  Drug transport across the blood-brain barrier. III. Mechanisms and methods to improve drug delivery to the central nervous system.

Authors:  J B Van Bree; A G De Boer; M Danhof; D D Breimer
Journal:  Pharm World Sci       Date:  1993-02-19

9.  Tamm-Horsfall protein regulates circulating and renal cytokines by affecting glomerular filtration rate and acting as a urinary cytokine trap.

Authors:  Yan Liu; Tarek M El-Achkar; Xue-Ru Wu
Journal:  J Biol Chem       Date:  2012-03-27       Impact factor: 5.157

10.  Pharmacokinetics of chlorambucil-tertiary butyl ester, a lipophilic chlorambucil derivative that achieves and maintains high concentrations in brain.

Authors:  N H Greig; E M Daly; D J Sweeney; S I Rapoport
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.